Interruption of marketing · 02.09.2026
Supply shortage Czechia: FIBROGAMMIN 250 250IU INJ/INF PSO LQF 1+1X4ML
Affected country: Czechia · Reported period: 31.08.2026 – 07.10.2026 · Active ingredient: KOAGULAČNÍ FAKTOR XIII
Notice context
A supply shortage has been recorded for FIBROGAMMIN 250 250IU INJ/INF PSO LQF 1+1X4ML in Czechia. The stated reason is “Capacity/distribution reasons”. The notice concerns the active ingredient KOAGULAČNÍ FAKTOR XIII and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Czechia. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for FIBROGAMMIN 250 250IU INJ/INF PSO LQF 1+1X4ML is a supply signal concerning KOAGULAČNÍ FAKTOR XIII in Czechia. The published reason “Capacity/distribution reasons” determines which data should be verified first.
For delivery or distribution issues, handover points, transport routes, temperature control, customs status, recipient authorisation and confirmed lead times should be checked.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess handover points, alternative routes, temperature, customs and recipient status, and confirmed lead times.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For distribution disruption, defined stock for FIBROGAMMIN 250 250IU INJ/INF PSO LQF 1+1X4ML in Cheb can support confirmed alternative routes to Czechia.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using record SÚKL-Code 0268840; Meldungs-ID 94544, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 31.08.2026 to 07.10.2026 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving FIBROGAMMIN 250 250IU INJ/INF PSO LQF 1+1X4ML: